This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.
Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...
Recursion Pharmaceuticals reported its second-quarter 2025 earnings with revenue significantly surpassing expectations, while earnings per share (EPS) fell short. The company posted an actual EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback